Cargando…
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas
Most pituitary adenomas (PAs) are considered benign tumors, but approximately 0.2% can present metastasis and are classified as pituitary carcinomas (PCs). Refractory PAs lie between benign adenomas and true malignant PC and are defined as aggressive-invasive PAs characterized by a high Ki-67 index,...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761748/ https://www.ncbi.nlm.nih.gov/pubmed/33362722 http://dx.doi.org/10.3389/fendo.2020.608422 |